11-77130638-G-C
Variant summary
Our verdict is Uncertain significance. The variant received 1 ACMG points: 2P and 1B. PM2BP4
The ENST00000409619.6(MYO7A):c.-110G>C variant causes a 5 prime UTR premature start codon gain change. The variant allele was found at a frequency of 0.000000684 in 1,461,038 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
ENST00000409619.6 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Publications
- nonsyndromic genetic hearing lossInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- autosomal recessive nonsyndromic hearing loss 2Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), PanelApp Australia, Ambry Genetics, G2P
- Usher syndrome type 1Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, PanelApp Australia
- Usher syndrome type 1BInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- autosomal dominant nonsyndromic hearing loss 11Inheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, PanelApp Australia, Labcorp Genetics (formerly Invitae)
- autosomal dominant nonsyndromic hearing lossInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hearing loss, autosomal recessiveInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- Usher syndrome type 2Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO7A | ENST00000409619.6 | c.-110G>C | 5_prime_UTR_premature_start_codon_gain_variant | Exon 2 of 50 | 1 | ENSP00000386635.2 | ||||
MYO7A | ENST00000409709.9 | c.4G>C | p.Val2Leu | missense_variant | Exon 2 of 49 | 1 | NM_000260.4 | ENSP00000386331.3 | ||
MYO7A | ENST00000458637.6 | c.4G>C | p.Val2Leu | missense_variant | Exon 2 of 49 | 1 | ENSP00000392185.2 | |||
MYO7A | ENST00000409619.6 | c.-110G>C | 5_prime_UTR_variant | Exon 2 of 50 | 1 | ENSP00000386635.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD2 exomes AF: 0.00000404 AC: 1AN: 247326 AF XY: 0.00000745 show subpopulations
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461038Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726678 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
The c.4G>C (p.V2L) alteration is located in exon 2 (coding exon 1) of the MYO7A gene. This alteration results from a G to C substitution at nucleotide position 4, causing the valine (V) at amino acid position 2 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at